T cell receptor-modified adoptive cell therapy (Medigene)

N/A

Report date: 2025/03/20 14:57:51

Base Information

Drug NameT cell receptor-modified adoptive cell therapy (Medigene)
Drug Alias NameT cell receptor-modified adoptive cell therapy (Trianta)T cell receptor-modified adoptive cell therapy (Helmholtz Zentrum Munchen/Max Delbruck)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionMelanoma-associated antigen 1 modulatorsT-cell receptor modulators
TargetsT-cell receptorMelanoma-associated antigen 1
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHelmholtz Zentrum Muenchen
China Registration ClassN/A

Develop Information

Active CompaniesMedigene Immunotherapies GmbH
Inactive CompaniesHelmholtz Zentrum MuenchenMax Delbruck Centrum Fur Molekulare Medizin
Active IndicationsNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A